KYTX — Kyverna Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $384.53m
- $213.59m
- 43
- 18
- 98
- 53
Annual balance sheet for Kyverna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 76.1 | 51.3 | 57.5 | 286 |
| Prepaid Expenses | ||||
| Total Current Assets | 77.1 | 53.3 | 60.7 | 291 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 7.81 | 12.4 | 10.6 | 10.7 |
| Other Long Term Assets | ||||
| Total Assets | 85.5 | 66.9 | 75.2 | 305 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 15.9 | 12 | 19.9 | 33.8 |
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 23 | 20.2 | 26 | 38.1 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Other Equity | ||||
| Total Equity | 62.5 | 46.7 | 49.2 | 267 |
| Total Liabilities & Shareholders' Equity | 85.5 | 66.9 | 75.2 | 305 |
| Total Common Shares Outstanding |